News and resources | Resources
Video 7 March 2013

Fake medicines – imminent risks to global health

By IFPMA
Share
Topics
Falsified medicinesTherapeutical products

Jamil Chade, Journalist
Mario Ottiglio, IFPMA
David Taylor, Professor of Pharmaceutical and Public Health Policy, UCL School of Pharmacy
Robert Johnstone, Board Member, IAPO
Luc Besancon, Acting General Secretary for Professional, Scientific and External affairs, International Pharmaceutical Federation
Martin Bernhardt, Vice President International Institutions, Sanofi

About IFPMA

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.

Learn more

Media Contact

Elliot Dunster

Related news and resources

Statement 5 Apr 2024

Enhanced collaboration between anti-doping agency and big pharma bolsters support for clean sport among athletes

On 3 April 2024 in Athens, the International Federationof Pharmaceutical Manufacturers and Associations (IFPMA) and the World Anti-Doping Agency (WADA) signed a joint letter of intent. 

Read more
Statement 6 Jun 2023

G20 side event on “Envisaging a Global R&D Network for Research in Vaccines, Therapeutics, and Diagnostics (VTDs) to enhance Prevention, Preparedness, and Response (PPR)”

On 6 June, IFPMA delivered a statement at the G20 “Strengthening Global Collaboration on Research and Development in MCMs (Diagnostics, Vaccines, and Therapeutics” side event on “Envisaging a Global R&D Network for Research in VTDs to enhance PPR” at the G20 3rd Health Working Group Meeting in Hyderabad.

Read more
Position paper 12 Apr 2023

Key considerations on the scope, utility and processes around updating the WHO Essential Medicines List

The WHO Essential Medicines List (EML) is an important tool in global health and supports the achievement of the UN Sustainable Development Goals. IFPMA has published perspectives from the R&D-based industry on the utility and scope of the EML. This position paper represents IFPMA's perspective as of April 2023, ahead of the publication of the revised version of the EML.

Read more
Top